Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be generalized to similar drugs but recognize that further studies will be needed," says first author Dr. Krastan Blagoev of the National Science Foundation. "Nevertheless, other drugs also approved worldwide for a variety of cancers-including sorafenib, pazopanib, and axitinib-are similar to sunitinib, and this will give some reassurances that one need not expect things to get worse after such drugs are discontinued."

Source: Cell Press

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New therapeutic target overcomes ovarian cancer immunotherapy resistance